ClinVar Miner

Submissions for variant NM_152419.3(HGSNAT):c.1360C>T (p.Gln454Ter)

dbSNP: rs1057518644
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000415469 SCV000794741 likely pathogenic Mucopolysaccharidosis, MPS-III-C 2017-10-16 criteria provided, single submitter clinical testing
Invitae RCV002521465 SCV003440195 pathogenic Mucopolysaccharidosis, MPS-III-C; Retinitis pigmentosa 73 2023-06-30 criteria provided, single submitter clinical testing Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 374408). This premature translational stop signal has been observed in individual(s) with mucopolysaccharidosis type III (PMID: 27733599). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gln454*) in the HGSNAT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HGSNAT are known to be pathogenic (PMID: 17033958, 19479962).
GENETICS INSTITUTE, National university of Colombia RCV000415469 SCV000323116 pathogenic Mucopolysaccharidosis, MPS-III-C 2016-03-01 no assertion criteria provided research As a result of genetic community visits in Boyacá, two patients with a phenotype compatible with MPS III in the village of Runta, adjacent to the city of Tunja rural area were identified. The research group Clinical Genetics at the National University of Colombia visited this place, leading to the identification of three more patients with the same presentation. In the first two cases identified, enzymatic assays for MPS III A and III B with negative results. Considering that MPS IIID is much less common, we considered MPS IIIC as a higher probability, so that the complete sequence of the gene HGSNAT, which revealed homozygous state, a new causal mutation was obtained. Mutation analysis in the remaining patients confirmed that all harboring the same mutation also in the homozygous state. All patients had coarse features that had become evident around 12 to 18 months and facial hirsutism. Hirsutism body was present in 80% of patients. Three patients had painful contractures of the large joints (hip, elbow and knee), as well as claw hand deformity. All patients had multiple disostosis and cranial hyperostosis and two patients had kyphosis. In all patients expressive language delay was presented, none of the patients becomes normal language for their chronological age, inattentiveness, echolalia and anxiety is evident.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.